Archive Press Release
(Products mentioned in this Archive Press Release may or may not be available from the manufacturer.)
Release date: August 13, 2007
Angiotech Announces Expansion of Innovative Quill(TM) SRS Product Line with New Choice of Absorbable Sutures
VANCOUVER, Aug. 13 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing a new polymer line of absorbable sutures, further broadening the offering of the Quill(TM) Self-Retaining System (SRS) product line.
Angiotech is launching MONODERM(TM), a new line of Quill(TM) SRS sutures made from a rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. The Quill(TM) SRS MONODERM(TM) sutures will be available in three different diameters.
"Since the initial launch of Quill(TM) SRS, we have received a tremendous amount of positive feedback and many requests to offer new iterations of the product line," said Dr. William Hunter, President and CEO of Angiotech. "We believe that these new, fast-degrading sutures are a great complement to the existing Quill(TM) SRS product line," added Dr. Hunter.
Angiotech intends to continue to expand the Quill(TM) SRS product line to cover multiple procedures for wound closure and tissue approximation.
It is expected that Angiotech will launch Quill(TM) SRS MONODERM(TM) in the fall, with plans to exhibit the Quill(TM) SRS product line at the Annual Meeting of the American Society of Plastic Surgeons (ASPS) to be held on October 26-31, 2007 in Baltimore, MD.
About the Quill(TM) Self-Retaining System (SRS)
The innovative Quill(TM) SRS represents the next generation of wound closure technology. A patented helical barbed design enables surgeons to suture without the use of knots. The absence of knots provides a wide range of clinical and economic benefits, including:
Potential to improve patient outcomes:
- Minimizes complications associated with knots
- Potential to improve wound healing
- May enhance cosmesis
Potential to save time in the operating room:
- Achieves potentially significant time savings, especially in suture intensive procedures
Enhanced procedural techniques:
- Allows closure of difficult wounds
- Enables suturing in tight places
- Allows the surgeon to control tension
Quill (TM) is a trademark of Quill Medical, Inc., a wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc.
MONODERM(TM) is a trademark of Surgical Specialties Corporation, a wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc.
About Angiotech
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), please visit our website at www.angiotech.com.
CONTACT: Jodi Regts, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930, jregts@angio.com
Company Information:
Name: Angiotech Pharmaceuticals, Inc.
Address: 1618 Station Street, V6A 1B6
City: Vancouver BC
Country: Canada
Phone: 604-221-7676
http://www.angiotech.com
|
|
|
Advertisement
|
| |
|
|
![[Get Copyright Permissions]](http://license.icopyright.net/images/icopy-w.gif){kind=small}
